slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 228,691-228,720
Pages 10,126
Rows per page 30
Component
228,691-228,720 of 303,780
11
Includes study references and definitions for GPR119, MASH, GLP-1, and drug dosages.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
12
The slide presents 11 distinct bar charts summarizing a study on drug efficacy in a mouse model of MASH (Metabolic dysfunction-associated steatohepatitis).NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations 1 hit
13
Notes at bottom define FPFV and LPO.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
14
The slide uses a hub-and-spoke diagram to illustrate the multi-faceted mechanism of action of the drug target.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
16
The table highlights DA-1726's dual agonist mechanism and potential for better tolerability compared to market leaders.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of oxyntomodulin.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
20
Includes study design, population, and location details.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Product1 hit
21
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Financials1 hit
22
WAEP stands for Weighted Average Exercise Price.NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Beat · Financials1 hit
23
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Why Now1 hit
24
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations Loop · Why Now1 hit
25
NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slidesNeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides · NeuroBo Pharmaceuticals
Pitch deck Investor relations 1 hit
02
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
03
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
05
Uses a personal narrative (Shay) to humanize the disease progression alongside clinical data.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Problem1 hit
06
The slide uses a biological mechanism-of-action diagram to illustrate how the two components of PrimeC address specific cellular stressors in ALS.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Agitate1 hit
08
The chart uses hazard ratio as a metric for efficacy in an iPSC model derived from ALS patients.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
10
Includes study design parameters (NST002) and key clinical outcomes.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
12
The slide uses a numbered list format to categorize clinical trial endpoints.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
13
The slide defines the statistical populations used for the clinical trial results.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
14
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
15
Shows balanced enrollment across key metrics like age, BMI, and disease severity (ALSFRS-R).NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
16
The slide highlights clinical trial safety data for PrimeC.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Before After1 hit
18
The slide uses a list of icons to anchor the clinical impact of the ALSFRS-R scale.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
22
The slide highlights the PARADIGM trial's research pillars, including proteomics, microRNA, exosomes, and neurofilaments, in partnership with institutions like MGH and Harvard.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
23
The slide uses a 'Case Study' to validate the company's own strategy of combination therapy.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit
24
NeuroSense Therapeutics | Investor Presentation Deck | 33 slidesNeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
25
The slide presents clinical biomarker data (Aβ40, Aβ42, Tau, pTau, PgJ2) comparing control vs AD groups, analyzed via Mann-Whitney U test.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
27
The slide uses a grid layout to present headshots and credentials, with institutional logos aligned below each relevant member.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit
28
The slide uses a grid layout to display logos of various research and clinical partners.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations 1 hit